Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Nippon Shinyaku Aims at 3% Growth in Mid, Long Term
March 19, 2007
- New Q&A Issued on Strengths of Generics
March 19, 2007
- NBI's Training System Boosts MR Productivity
March 19, 2007
- Ain Pharamaciez to Sell Generics Outside Group from April
March 19, 2007
- BUSINESS NEWS IN BRIEF
March 19, 2007
- MEDICAL DEVICE NEWS IN BRIEF
March 19, 2007
- 7 APIs Including Celecoxib to Be Included in NHI Price List
March 19, 2007
- Efficacy of Narcotic Analgesics Predicted by Gene Polymorphisms
March 19, 2007
- Gov't-Private Sector Dialogueto Be Held on Distribution
March 19, 2007
- Consider Licensing, Not Independent Marketing, in Advanced Countries: Mr Seko
March 19, 2007
- Warning against Exacerbation of Hepatitis Added to Package Insert of Rituximab
March 19, 2007
- Amended PAL Presents Opportunities: JACDS
March 19, 2007
- REGULATORY NEWS IN BRIEF
March 19, 2007
- 6-Year Education Makes Schools of Pharmacy Less Attractive: Survey
March 19, 2007
- PMDA to Hire 236 New Reviewers by End of FY2009
March 19, 2007
- Global Sales of 3 New Strategic Products to Exceed US$1.5 Bil. Each: Mr Naito
March 19, 2007
- Nipro: SURELYZER PES-a
March 12, 2007
- Results of JPHC Study Announced
March 12, 2007
- Synergy NeuroStimulator from Medtronic, A New Option for Severe Chronic Pain: Dr Abe
March 12, 2007
- DSP to Start 3-Year Approach Run to Go Fully Global: Mr Miyatake
March 12, 2007
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…